PhilipMartinArlenMD

Oncology • Bethesda, MD

Physician

Join to view full profile

Dr. Arlen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Arlen's full profile

Already have an account?

Office
10 Center Dr
Rm 8B09
Bethesda, MD 20892
Phone+1 301-493-4231

Education & Training

National Cancer InstitutePost-Doctoral Fellowship, 1997 - 1999
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 1994 - 1997
Wellstar Health System/Wellstar Cobb HospitalResidency, Internal Medicine, 1991 - 1994
Medical College of Georgia at Augusta UniversityClass of 1991

Certifications & Licensure

MD State Medical License 1999 - 2026
GA State Medical License 1992 - 2025
FL State Medical License 2016 - 2021
American Board of Internal Medicine Medical Oncology

Clinical Trials

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer Start of enrollment: 2000 Jun 01
Completed
Phase 2
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2002 Aug 01
Completed
Phase 2
Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer Start of enrollment: 2002 Sep 01
Completed
Phase 2
Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery Start of enrollment: 2004 Aug 01
Completed
Not Applicable
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 1, Phase 2
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Start of enrollment: 2019 Jan 15
Not yet recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells.
Massimo Fantini, Kwong Y Tsang, Philip M Arlen
Expert Review of Vaccines. 2024-09-01
2 citations
Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide.
Shruti U Gandhy, Fatima H Karzai, Marijo Bilusic, Sheri McMahon, Lisa M Cordes
European Urology Oncology. 2024-08-01
4 citations
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
Ravi A Madan, Marijo Bilusic, Mark N Stein, Renee N Donahue, Philip M Arlen
The Oncologist. 2023-07-05

Journal Articles

arlen p

Press Mentions

Cancer Vaccines: New Targeting Strategies, Brighter ProspectsAugust 8th, 2024

Grant Support

Clinical Trials Involving Vaccine And Standard Of Care Cancer TherapiesNational Cancer Institute2008
Vaccine Clinical TrialsNational Cancer Institute2007
Vaccine Clinical TrialsDivision Of Basic Sciences - Nci2005–2006

Professional Memberships

American Society of Clinical Oncology - ASCO
Member